Health Condition 1: L732- Hidradenitis suppurativa
Conditions
Interventions
Intervention1: Oral tofacitinib: Oral tofacitinib 5 mg twice daily
Duration: 6 months
Control Intervention1: Not applicable as single arm study: Not applicable as single arm study
Sponsors
none
Eligibility
Inclusion criteria
Inclusion criteria: 1 diagnosis confirmed by European S1 guideline criteria presence of characteristic lesions in typical anatomical distributions with chronic or recurrent progression 2 refractory disease documented inadequate response or intolerance to upto or more than 2 prior systemic therapies including antibiotics, biologics, or immunosuppressants 3 availability of complete baseline data with a minimum 12week follow-up
Exclusion criteria
Exclusion criteria: concurrent use of other HS targeted systemic therapies or pregnancy or lactation status
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome Hidradenitis Suppurativa Clinical ResponseTimepoint: Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes included absolute changes in Sartorius score Pain Numerical Rating Scale scores Dermatology Life Quality Index scores from baseline through 36 weeks along with timeto first flare following treatment discontinuationTimepoint: week 36 | — |
Countries
India
Contacts
Public ContactDr Bushra Iqbal Khan
Government Medical College and Hospital Nagpur
Outcome results
None listed